Zhao FY, Wang DY, Qian NS. Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach. World J Gastrointest Oncol 2024; 16(10): 4042-4044 [PMID: 39473949 DOI: 10.4251/wjgo.v16.i10.4042]
Corresponding Author of This Article
Nian-Song Qian, MD, Chief Physician, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100091, China. qianniansong1@163. com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4042-4044 Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4042
Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach
Fei-Yu Zhao, Dong-Yu Wang, Nian-Song Qian
Fei-Yu Zhao, Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100853, China
Dong-Yu Wang, Department of Nephrology, General Hospital of the People’s Liberation Army, Beijing 100853, China
Nian-Song Qian, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, Beijing 100091, China
Author contributions: Qian NS came up with the idea for the article; Zhao FY carried out the writing of the article; and Wang DY was responsible for revising the article.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4. 0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nian-Song Qian, MD, Chief Physician, Senior Department of Thoracic Oncology, Respiratory and Critical Care Medicine, The Eighth Medical Center of People’s Liberation Army General Hospital, No. 28 Fuxing Road, Beijing 100091, China. qianniansong1@163. com
Received: February 28, 2024 Revised: May 11, 2024 Accepted: June 11, 2024 Published online: October 15, 2024 Processing time: 211 Days and 8.4 Hours
Abstract
In this editorial, we review the article “Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma”. We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma. Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer, but the combination of all three therapeutic approaches needs more research.
Core Tip: This article focuses on the efficacy of transarterial chemoembolization combined with lenvatinib in combination with programmed death 1 inhibitors in patients with advanced hepatocellular carcinoma. Although transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 have both achieved some efficacy in advanced hepatocellular carcinoma, more clinical evidence is needed on the efficacy of all three combinations.
